Primidone

Primidone is a barbiturate-related anticonvulsant, structurally a close congener of phenobarbital. An important feature of the drug is its metabolism: in the body it is broken down into two active compounds, phenobarbital and phenylethylmalonamide (PEMA), which contribute substantially to its overall effect ^[1].

The compound's usefulness against epilepsy was demonstrated at the end of the 1940s, and it was marketed from 1950 in Europe before being introduced in the United States in 1954 under the brand name Mysoline. It is now a long-established generic medicine.

Primidone has two main roles. In epilepsy it is used for partial and generalized tonic-clonic seizures. A large double-blind comparative trial found that it controlled tonic-clonic seizures about as well as carbamazepine, phenytoin and phenobarbital, but that it caused more intolerable early side effects such as nausea, dizziness and sedation, which is why other agents are generally preferred as first choices ^[1]. Its second, and today perhaps most prominent, role is in essential tremor: alongside propranolol it is regarded as a first-line drug, rated as effective for reducing limb tremor in formal treatment guidelines ^[2], and current reviews of essential tremor continue to list propranolol and primidone as the mainstays of medical therapy ^[3].

Primidone is a prescription medicine supplied as tablets and as an oral suspension. Because it is converted to phenobarbital, it shares that drug's tendency to cause drowsiness and unsteadiness, to induce liver enzymes and thereby interact with many other medicines including oral contraceptives, and to carry risks in pregnancy such as birth defects and a bleeding tendency in newborns ^[4]. Treatment is usually started at a low dose and increased slowly to improve tolerability.

Primidone is prescription only and is a controlled substance in many places because it forms phenobarbital. When first started it can cause an acute intolerance reaction with strong dizziness, nausea and unsteadiness, which is why doctors begin at a tiny bedtime dose. Ongoing effects include sedation, drowsiness, poor balance and, with long use, folate-related anemia, softened bones from vitamin D changes and physical dependence. As a liver enzyme inducer it speeds the breakdown of many drugs, including warfarin, birth control pills and other seizure medicines, so combinations need review. It adds to the effect of alcohol and other sedatives and should not be stopped abruptly.

Primidone was developed by the British pharmaceutical company Imperial Chemical Industries and introduced in the early 1950s, reaching the market under the brand name Mysoline as an anticonvulsant for epilepsy. Chemically it is closely related to phenobarbital, and researchers soon established that much of its therapeutic effect arises because the body converts it into two active substances, phenobarbital and phenylethylmalonamide.

Over subsequent decades its usefulness broadened well beyond seizures; it became recognized as one of the two most effective medicines for essential tremor, a role it still holds alongside propranolol as a first-line option in modern consensus guidance. Its long clinical history has also clarified its limitations, including a tendency toward early adverse reactions such as sedation and unsteadiness, which reviews note are more prominent in tremor patients than in those treated for epilepsy. Now an inexpensive generic, primidone remains a durable and clinically important drug more than seventy years after its introduction.

Primidone has earned a lasting reputation as a workhorse of neurology, one of only two front-line drugs proven to quiet the shaking of essential tremor. Physicians value it because low, carefully titrated doses can meaningfully reduce tremor amplitude, often improving handwriting, eating and daily tasks for people who have struggled for years. Its long track record and low cost as a generic make it accessible worldwide, and its dual identity as both a direct anticonvulsant and a precursor of phenobarbital gives it a well-understood pharmacology. Candor requires noting that it can cause pronounced drowsiness, dizziness and nausea, particularly when first started, and that it interacts with many other medicines through liver enzyme induction. Started gently and built up slowly, however, it continues to be a genuinely effective and trusted therapy for tremor and epilepsy alike.